Business
Seegnal Inc. Establishes Strategic Commercialization Team and Appoints Arx as Investor Relations Advisor
Seegnal Inc. Establishes Strategic Commercialization Team and Appoints Arx as Investor Relations ...
About this update from Seegnal Inc.
[{"type":"text","content":"\n\n\nSeegnal Inc. Establishes Strategic Commercialization Team and Appoints Arx as Investor Relations Advisor\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nCanada NewsWire\n\n\nCompany Advances Market Expansion Initiatives While Strengthening Capital Markets InfrastructureCALGARY, AB, April 1, 2026 /CNW/ - Seegnal Inc. (TSXV: SEGN) (\"Seegnal\" or the \"Company\"), a global leader in clinical decision support solutions applying patient-centric medication safety standards, today announced the formation of a dedicated Strategic Commercialization Team led by its Chief Executive Officer, and the engagement of CapitaLynx Ltd. (operating as \"Arx\") as its investor relations advisor.\nEstablishment of Strategic Commercialization TeamSeegnal has established a cross-functional Strategic Commercialization Team tasked with accelerating the Company's go-to-market execution across target healthcare systems and geographies. The team is led directly by the Chief Executive Officer and includes senior members representing clinical affairs, business development, regulatory strategy, and technology integration.The formation of this team reflects the Company's transition into a structured commercialization phase following the successful deployment and clinical validation of its medication safety platform at leading healthcare institutions. The team is responsible for managing strategic partnerships, contract negotiations, and revenue-generating deployment pipelines.\"Establishing a dedicated commercialization team is a defining step in Seegnal's evolution from clinical proof-of-concept to scalable market presence,\" said Elad Bibi-Aviv, Chief Executive Officer of Seegnal. \"We are executing with clarity and urgency, and our team has the operational depth to convert our clinical track record into sustained commercial momentum.\"Engagement of Arx as Investor Relations Advisor Pursuant to TSXV Policy 3.4, Seegnal announces that it has engaged CapitaLynx Ltd. (\"Arx\") to provide technology-powered investor relations services commencing on April 1, 2026...